Kornimate/medical-research-clean huggingface dataset:
the effect of femoral nerve block on postoperative opioid use after anterior cruciate ligament (acl) reconstruction

Conditions: Pain, Postoperative

Summary: this study evaluates the effect of a femoral nerve block on opioid requirements following anterior cruciate ligament (acl) reconstruction. this is a double blind, prospective randomized controlled trial.


Eligibility criteria:
inclusion criteria: * schedule for primary elective anterior cruciate ligament reconstruction * tolerance to bupivacaine * tolerance to non-steroidal anti-inflammatory drugs (nsaids) * informed consent exclusion criteria: * patients who received a femoral nerve block more than 1 hour prior to surgery * complex associated injuries or pre-existing conditions that will delay time to ambulation * children with tibial avulsion fractures * allergic and/or sensitive to bupivacaine and/or nsaids * 30% over ideal body weight * acute acl reconstruction (done less than 2 weeks after injury) * pre-existing femoral nerve injury * psychiatric patients on psychotropic agents * history of drug or alcohol dependence or recreational drug use * refusal to provide informed consent

Keywords: acl reconstruction morphine sparing preemptive analgesia post-operative pain and post- operative opioid use
adding urea to the final dialysis fluid

Conditions: Dysequilibrium Syndrome; ESRD; Hyperkalemia; Metabolic Acidosis

Summary: at times patients with advanced renal failure present with severe hyperkalemia or acidosis and very high serum blood urea nitrogen (bun) concentrations. these patients cannot be dialyzed aggressively as the lowering of serum bun may results in disequilibrium syndrome but on the other hand they need aggressive dialysis in order to lower their serum potassium or fix their severe acidosis. if one is able to add urea to the dialysis fluid, one can prevent the rapid lowering of serum bun and osmolality at the same time as doing aggressive dialysis to lower serum potassium and/or fix the metabolic acidosis.

ure-na 15 gram tablets would be used to add to the dialysis fluid how much urea to add would be a simple calculation based on the 45x dialysis system and the patients serum urea concentration. the dialysate fluid urea concentration would be made to be about 15-40 mg/dl lower than the serum concentration. the patients labs/vitals and symptoms would be closely monitored throughout the dialysis treatment.

Eligibility criteria:
inclusion criteria: * serum urea \> 120 * serum potassium \> 5.5 or serum co2 \< 15 or need for aggressive dialysis due to toxic ingestion * need for dialysis exclusion criteria: * pediatric * need for crrt

Keywords: esrd urea disequilibrium potassium acid/base
effects of nutraperf consumption in runners

Conditions: Nutrition Processes

Summary: exercise has numerous health benefits. nevertheless, when exercise duration is \~45 min or longer and intensity moderate to intense, it may induce different troubles, for example: hypoglycemia, peripheral and central fatigue, muscle damages, osteoarticular injuries, inflammation, cardiovascular dysfunctions. nutritional loading during exercise may prevent and and/or reduce some of these troubles. in regard of recent data, we proposed a novel energy drink (nutraperf®) to limit deleterious effects of long time exercise in neutral environment (outside temperature between 4 and 25°c) and to improve performance. if performance may be increased by this energy drink during long time exercise, we proposed that it consumption may also improve performance in short and sub-maximal exercise. so, the purpose of this study is to investigate the effects of the consumption of this novel energy drink on performance during long and short time exercise. moreover, we studied the effects of this consumption on different metabolic parameters (heart rate, oxygen consumption, respiratory quotient, ventilation, glycemia, lactatemia), on central and peripheral fatigue and on cognitive parameters.


Eligibility criteria:
inclusion criteria * man aged between 18 and 45 years. * regular sportsman (2 to 4 workouts by week since 3 months minimum). * be a long-distance runner. * be affiliated or beneficial to the national french security social. non-inclusion criteria * any subject who was injured during the three preceding months study. * any subject with a history of disease can disrupt the tests. in particular, subjects with pathological conditions placed on the joints of the knee or ankle (sprain repeated problems or patellar ligament) that could hamper measures of force maximum extension and flexion on these joints or illnesses that prevent the exercise of pedalling or running on treadmill (tendonitis, periostitis) will be excluded. * any subject who at the same time participates at another medical experiment.

Keywords: energy drink exercise bcaa peripheral and central fatigue
comparison of n2o inhalation and ketamine in pediatric psa

Conditions: Moderate Sedation; Laceration

Summary: * ketamine provides effective and relatively safe sedation analgesia for primary closure of lacerated pediatric patients * however, deep sedation and adverse effects suggest the opportunity to develop alternative strategies * we compared the efficacy and adverse effects of ketamine to those of n2o gas for analgesia and anxiolysis during primary repair of lacerated pediatric patients

* there were 32 children who were randomly assigned * recovery times were markedly shorter in the n2o group compared with those in the ketamine group (median, 0.0 min (interquartile range \[iqr\], 0.0-4.0 min) vs. median, 21.5 min (iqr, 12.5-37.5 min), n2o vs. ketamine, respectively, p \< 0.05) * sedation levels were deeper in the ketamine group than in the n2o group, but pain scales were comparable between groups * no difference was observed in the satisfaction scores by physicians, parents, or nurses. * n2o inhalation was preferable to injectable ketamine for pediatric patients because it is safe, allows for a faster recovery, maintains sufficient sedation time, and does not induce unnecessarily deep sedation

Eligibility criteria:
inclusion criteria: * pediatric patients with lacerated wound exclusion criteria: * contraindication of ketamine or n2o gas * a wound around eye and mouth
the effect of systemic lidocaine infusion to postoperative pain and quality of recovery after laparoscopic hernia repair in children

Conditions: Inguinal Hernia

Summary: systemic lidocaine administration may improve postoperative pain and recovery after laparoscopic inguinal hernia repair in pediatric patients


Eligibility criteria:
inclusion criteria: * age between 1 and 6 year-old * asa class 1 and 2 * pediatric inguinal hernia patients who are scheduled for elective laparoscopic inguinal hernia repair exclusion criteria: * allergy to local anesthetics or contraindication to use of lidocaine * current active upper respiratory infection or history of upper respiratory infection within 2 weeks * severe cardiovascular disease * renal failure * liver failure * neurologic and psychologic disease * chronic treatment with analgesics * previous history of laparoscopic operation * parents' refusal

Keywords: systemic lidocaine postoperative pain recovery, pediatric inguinal hernia laparoscopy
vitamin k2 and muscle weakness in type 2 diabetes

Conditions: Diabete Type 2

Summary: the aim of the current study is to determine the effects of vitamin k2 supplementation on muscle size and function in adults with muscle weakness and type 2 diabetes.


Eligibility criteria:
inclusion criteria: * physician confirmed type 2 diabetes. * age \>/= 40 years * no changes in anti-diabetic medication in the last 3 months. * muscle weakness (grip strength \<27kg and females \<16kg) exclusion criteria: * bmi of 45 or higher * bp of 160/100mmhg or higher * cancer or cancer that has been in remission \<5 years * any medical condition that prevents participants from exercising safely * on anticoagulant therapy * currently consuming vitamin k2 supplements * current smoker
the complete® self-expanding stent and stent delivery system registry

Conditions: Peripheral Vascular Disease

Summary: the purpose of this study is to show if a new delivery system with a modified stent is safe in treating occluded iliac arteries in patients with peripheral vascular disease. the modified complete se delivery system is hypothesized to assist physicians with more accurate stent placement reducing the likelihood of stent 'jumping' seen with the use of many self-expanding stent systems.

the study is being conducted to collect the 30-day safety data on the stent delivery system for all subjects enrolled into the study (with a minimum of 50 subjects enrolled) as well as the long-term 9-month safety and efficacy data on all subjects enrolled (with a minimum of 10 subjects enrolled into the study having the 120mm length stent implanted).

Eligibility criteria:
inclusion criteria: * the lesion(s) is either de-novo or restenotic in nature, located in either the common iliac artery or the external iliac artery and is \>50% stenosed * target vessel reference diameter ≥ 4.5 mm and ≤ 9.5 and can accommodate stent diameters of 6.0 - 10.0mm * subject is either asymptomatic with a lesion stenosis ≥70% or symptomatic with a lesion stenosis ≥50% with an ankle brachial index (abi) \< 0.90 or toe brachial index (tbi) \<0.80 or an abnormal pulse volume recording (pvr); * total lesion length is \< 110 mm; exclusion criteria: * excessive peripheral vascular disease (pvd), unresolved fresh thrombus or tortuosity or a target lesion/vessel that is heavily calcified ; * tissue loss in the extremity: category 5 or 6 on the rutherford scale; * target lesion has a previous stent, or is within a prosthetic vascular bypass graft or within 1 cm of a graft anastomosis; * target lesion is within an aneurysm or associated with an aneurysm in the vessel segment proximal or distal to the target lesion; * lesion requires treatment with a non-standard device associated with percutaneous transluminal angioplasty (pta) prior to stent placement; * inadequate distal run-off; * planned interventional procedure or vascular surgery to target vessel within 30 days pre- or post-index iliac procedure; * history of bleeding diatheses or coagulopathy or will refuse blood transfusions; * platelet count \ 700,000 cells/mm3, or white blood count (wbc) \<3,000 cells/mm3; * creatinine \>2.0 mg/dl; * participation in another investigational device or drug study and has not completed the primary endpoint(s) follow-up phase of that study at least 30 days prior to enrollment in this trial or the subject has previously been enrolled in this registry;

Keywords: iliac artery, peripheral vascular disease (pvd)
evaluating a remotely delivered plant-based behavioral weight loss treatment

Conditions: Obesity; Overweight

Summary: many individuals do not achieve clinically significant weight loss following traditional lifestyle modification interventions, potentially because weight loss is dependent upon calorie tracking compliance (to achieve calorie prescriptions), which decreases over time for most. by contrast, non-energy-restricted whole food plant-based diets (wfpbd) have been demonstrated to promote clinically significant weight loss even without calorie prescriptions. the present pilot trial represents the first, to the knowledge of our study team, to empirically test a remotely delivered wfpbd behavioral weight loss intervention for adults with overweight or obesity. over 12-weeks, participants (n = 21) will follow a non-energy-restricted wfpbd and received nutritional counseling and behavioral weight loss intervention. participation will occur in two phases (phase 1: n = 7; phase 2: n = 14), between which iterative changes to the intervention will be made. assessments will occur at baseline, mid-treatment, post-treatment, and 3-month follow-up. data will be analyzed using an intent-to-treat approach. the primary aims of the study will be to assess retention feasibility and acceptability. the secondary aims will be to evaluate the preliminary effectiveness of the intervention on: (1) percent weight loss; (2) dietary intake (i.e., increased intake of low-fat plant-based whole foods and decreased in intake of processed foods and animal products); and (3) waist circumference. the exploratory aims will be to evaluate the preliminary effectiveness of the intervention on physical- and mental health-related quality of life, and to examine potential moderators of treatment success (plant-based diet history, internal disinhibition, social support vs. social sabotage, self-compassion, and psychological flexibility).


Eligibility criteria:
inclusion criteria: * aged 18-75 * current bmi ≥ 25 kg/m2 * reporting a desire to lose weight * have at-home internet access * proficiency in speaking, reading, and writing english * willing to consume a whole foods plant-based diet for the study duration exclusion criteria: * use of medications for weight loss * recent weight loss (≥5% weight loss in prior 3-months) * current or planned pregnancy within the study period * history of bariatric surgery * currently following a low-fat plant-based diet * diagnosis of a serious medical condition influencing weight, appetite, or eating behavior * diagnosis of a serious psychiatric condition that may influence weight, appetite, or eating behavior * current substance use disorder * participation in a concurrent weight loss program * planning on quitting smoking over the intervention period (if current smoker) * eating pathology (lifetime history of an eating disorder, ≥ 9 binge eating episodes in the past 3 months, or \> 5 compensatory episodes in the past 3 months)

Keywords: weight loss behavioral weight loss overweight and obesity plant-based lifestyle modification
the microvascular brain retina and kidney study

Conditions: Cerebral Small Vessels Disease

Summary: cerebral small vessel disease (csvd) is a major cause of cognitive impairment and disability in the general population, secondary to the accumulation of asymptomatic elementary lesions. csvd is directly correlated with age and cardiovascular risk factors and therefore would be challenging in term of public health care in the future. while hiv patients share the same cardiovascular risk factors and they are often diagnosed with cognitive impairment and frailty, csvd has not been yet described in this population. the global aim is to study and describe the csvd in the hiv+ population by: (1) correlating the csvd and the macro-vascular disease of the head and brain; (2) correlating the csvd with the ocular (structural sentinel organ) and kidney (functional sentinel organ) micro-vascular disease. hiv+/csvd+ patients will have a complementary work-up with conventional mri/mra, thorough vascular explorations, and neurologic examination to evaluate the severity of the csvd, the macro-vascular disease and the cerebral atrophy. they will have a full ophthalmic examination and specific kidney explorations to evaluate the micro-vascular disease of this two sentinel organs. the same number of hiv+/csvd- matched patients will have the same work-up. we are expecting to show the relationship between csvd and cardiovascular risk factors in order to propose specific prevention. we will correlate the csvd with the neurologic and cognitive function as it is already proved in the general population. we will correlate the csvd with the ocular and kidney micro-vascular disease to propose fast, easy and cheap screening tools for the csvd in the hiv+ population.


Eligibility criteria:
inclusion criteria: * age over 50 years old * chronic hiv seropositive patient infected for at least 5 years * antiretroviral therapy * plasmatic hiv viral load \<40 copies/ml for at least one year with one authorized blip \< 1000 copies/ml per year * cerebral small vessels disease (patients) or not (controls) exclusion criteria: * co-infection vhc * known antecedent of stroke * documented neurologic complication of hiv * drug user * glomerular filtration rate\< 15 ml/mn * diabetic patient with kidney or retin complications * systolic blood pressure≥ 180 and/or diastolic blood pressure≥ 110 mmhg
open label trial of utility of cryobiopsy in the multidisciplinary diagnosis of idiopathic interstitial lung disease

Conditions: Interstitial Lung Disease

Summary: a multicenter, multinational, prospective study to clarify, whether the addition of cryobiopsy can avoid surgical lung biopsy in a clinically relevant proportion of patients with suspected idiopathic interstitial pneumonia


Eligibility criteria:
inclusion criteria: * iip suspected on clinical and radiologic grounds exclusion criteria: * age \>80y and \<18y * fvc\< 55%, dco\<35% * platelet count \<100000/µl * acetylsalicylic acid, clopidogrel or equivalent during the last 5 days * inr \> l,3, * elevated ptt (\> 40 s) * documented pulmonary hypertension paps \>50mmhg * hr-ct highly suspicious for sarcoidosis

Keywords: cryobiopsy lung biopsy interstitial lung disease
exit interviews to assess impact of infusion frequency in hemophilia a

Conditions: Hemophilia A

Summary: this study is to generate qualitative data to evaluate the impact of frequency of fviii infusions on patients' satisfaction with treatment and their quality of life.


Eligibility criteria:
inclusion criteria: * patient is enrolled in the bay94-9027 extension studies or is within 3 months of having completed participation in the bay94-9027 extension studies; * patient allocated to arm 2, arm 3 or arm 4 of bay94-9027 extension studies. * arm 2 prophylaxis treatment of bay94-9027; 2 infusions per week during the extension study * arm 3 prophylaxis treatment of bay94-9027; infusion every 5 days during the extension study * arm 4 prophylaxis treatment of bay94-9027; every 7 days during the extension study * evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study; * patient must be willing and able to participate in a telephone interview lasting up to 30 minutes; * patient must have sufficient cognitive and linguistic capacities to allow them to actively participate in an interview lasting 30 minutes. exclusion criteria: * patient is part of arm 1: on-demand treatment of bay94-9027 at individual dose and number of infusions based upon location and severity of bleeds; * patient is unlikely to comply with the study protocol (e.g. uncooperative attitude) or unlikely to complete the study for any reason in the opinion of the recruiter; * patient has great difficulty hearing or reading; * patient has any significant comorbid condition (including uncontrolled psychiatric conditions) that might limit or interfere with their ability to talk about their hemophilia a and participate in the study; * patient has severe neurological or cognitive deficits that might affect their ability to participate in an interview.
rectal versus intramuscular diclofenac for pain relief following caesarean section

Conditions: Painrelief; Postoperative

Summary: caesarean section (cs) is one of the commonest major obstetric surgeries worldwide and its rate has markedly increased globally. pain control is an integral part of enhancement of recovery after caesarean section and nsaids have been used in combination with opioids for post-operative pain management in recent times. there are sparse data on maternal satisfaction with suppository diclofenac or any data from our centre that compared the intramuscular and rectal routes of diclofenac administration. hence this study was conceived to compare the efficacy of rectal diclofenac and intramuscular diclofenac as an adjunct to intramuscular pentazocine in the management of post-operative pain in women who have elective caesarean section.

background: caesarean section (cs) is one of the commonest major obstetric surgeries worldwide and its rate has markedly increased globally. pain control is an integral part of enhancement of recovery after caesarean section and nsaids have been used in combination with opioids for post-operative pain management in recent times. there are sparse data on maternal satisfaction with suppository diclofenac or any data from our centre that compared the intramuscular and rectal routes of diclofenac administration. hence this study was conceived to compare the efficacy of rectal diclofenac and intramuscular diclofenac as an adjunct to intramuscular pentazocine in the management of post-operative pain in women who have elective caesarean section. aim: this study is designed to compare the efficacy of rectal diclofenac with that of intramuscular diclofenac as pain relief among women after elective caesarean section at alex-ekwueme federal university teaching hospital, abakaliki. methods: this was a randomized equivalence controlled trial conducted among pregnant women booked for elective caesarean section at alex-ekwueme federal university teaching hospital abakaliki, comparing the efficacy of rectal diclofenac with that of intramuscular diclofenac as pain relief among women after elective caesarean section at term. one arm received 100mg of suppository diclofenac and the other arm received 75mg of intramuscular diclofenac. these doses were repeated every 12hours for 24 hours. pain scoring was done at 1, 6, 12, 18 and 24 hours after administration of the drugs. the data obtained was analysed using ibm spss software (version 23, chicago ii, usa) and the intention to treat concept. a difference with a p value of ≤ 0.05 was taken to be statistically significant.

Eligibility criteria:
inclusion criteria: * elective caesarean section at term with spinal anaesthesia;e exclusion criteria: 1. allergy to nsaids 2. bleeding diathesis 3. use of general anesthesia 4. chronic liver disease 5. history of renal disease 6. asthma in pregnancy 7. emergency cesarean section 8. morbid obesity 9. sickle cell anaemia patients 10. hypertensive disorders of pregnancy 11. refusal to give consent

Keywords: rectal diclofenac caesarean section